Clinical Trials In Houston
Discover hundreds of clinical trials in Houston.
Search clinical trials in Houston by condition or phase.
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
Sponsor:
AbbVie
Location:
Code:
NCT04777357
Conditions
Depression
Bipolar I Disorder
Eligibility Criteria
Sex: All
Age: 10 - 17
Healthy Volunteers: Not accepted
Interventions
Cariprazine
Placebo
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
Sponsor:
Baylor College of Medicine
Location:
Code:
NCT02291848
Conditions
Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
TAA-specific CTLs
TAA-specific CTLs- fixed dose
Phase 1 Trial of ST-001 NanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Sponsor:
SciTech Development, LLC
Location:
Code:
NCT04234048
Conditions
T-cell Lymphoma
Cutaneous/Peripheral T-Cell Lymphoma
Peripheral T-cell Lymphoma
Peripheral T-Cell Lymphoma, Not Classified
Primary Cutaneous T-cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Fenretinide
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Sponsor:
Janssen Research & Development, LLC
Location:
Code:
NCT05754957
Conditions
Acute Coronary Syndrome
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Milvexian
Placebo
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03871257
Conditions
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
Eligibility Criteria
Sex: All
Age: 2 - 21
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Selumetinib Sulfate
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
Sponsor:
Replimune Inc.
Location:
Code:
NCT03767348
Conditions
Cancer
Melanoma (Skin)
Mismatch Repair Deficiency
Microsatellite Instability
Non-melanoma Skin Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
RP1
nivolumab
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
Sponsor:
Amneal Pharmaceuticals, LLC
Location:
Code:
NCT05401357
Conditions
Glaucoma, Open-Angle
Ocular Hypertension
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Test - Bimatoprost 0.01% Ophthalmic Solution
Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
Sponsor:
M.D. Anderson Cancer Center
Location:
Code:
NCT06083857
Conditions
Non-small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Amivantamab
Tepotinib
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
Sponsor:
Jiangsu Simcere Pharmaceutical Co., Ltd.
Location:
Code:
NCT05569057
Conditions
Advanced Solid Tumor
Cutaneous T-cell Lymphoma (CTCL)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
SIM1811-03
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Sponsor:
Novartis Pharmaceuticals
Location:
Code:
NCT04174157
Conditions
Spinal Muscular Atrophy (SMA)
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Prospective observational registry
Zolgensma